Alume Biosciences Announces First Patient Dosed with ALM-488 in Phase III Pivotal Study in Patients Undergoing Head and Neck Surgery

Alume Biosciences, Inc. announced that the first patient has been dosed in a Phase III pivotal study of ALM-488, a peptide-dye conjugate that binds to the ECM of nerves, allowing real-time nerve illumination during surgery.